All News
RheumNow Podcast - COVID Kids and Men (5.15.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticleNew ACR Guidelines for Gout Management
The ACR has published the 2020 guidelines on the management of gout that includes strong recommendations favoring treat‐to‐target management and starting urate lowering therapy (ULT) for patients with frequent flares, radiographic damage or tophi due to gout.
Read ArticleRheumNow Podcast – Drive Them Crazy (4.17.20)
Dr. Jack Cush reviews the news, journal articles and new ACR COVID-19 guidelines from the past week on RheumNow.com.
NICE Guidelines on Managing Rheumatologic Conditions During COVID-19 Pandemic
On April 3rd, the National Institute for Health and Care Excellence (NICE) in the UK, published a rapid guideline for managing children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection.
Read ArticleGlobal Rheumatology Alliance Registry Will Study COVID-19
In the midst of a global pandemic of the 2019 Novel coronavirus acute respiratory disease (COVID-19), a small handful of Rheumatologists gathered on social media to collectively grapple with the impact of this virus on vulnerable populations with rheumatic disease.
Need for Disruptive Innovation in Rheumatology
A full-read, novel Viewpoint article published in the Annals of Rheumatic Disease (Huizinga TWJ, et al) spotlights a recent international meeting of big thinkers, scientific collaborators and industry dedicated to innovation in rheumatology.
Read ArticleInterleukin-37 Targeting in Gout
The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.
Read ArticleRheumNow Podcast- Methotrexate Mechanisms (2.28.20)
Dr Jack Cush Reviews the news and journal articles from the past week on RheumNow.com
Read ArticleMethotrexate and the Risk of Lung Disease
Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; r
Read ArticleHyperuricemia Predisposes to Coronary Artery Disease in Men
There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.
Read ArticleRheumNow Podcast- Half-Empty Flu (2.21.20)
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read ArticleHypersensitivity Reactions and Gout Tx: Watch the Dose
Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.
Read ArticleRheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticleNSAID Safety Guidelines
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for acute or chronic arthritis, headache, visceral pain, postoperative pain, etc but come with a small but significant risk of serious adverse effects, including hypertension, cardiovascular disease, kidney injury and GI complica
Read ArticleDiabetics using SGLT2 Inhibitors have a lower Gout Risk
Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).
Read ArticleA Role for SGLT2 Inhibition in Gout?
The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.
Read ArticlePredicting Inpatient Gout Flares
Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.
This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.
Read ArticleRheumNow Podcast - The Elusive Hand OA Problem (12.13.19)
Dr. Jack Cush recaps the news and journal reports from the past week on RheumNow.com.
Read ArticleRheumNow Podcast - Monitoring Methotrexate Safety (12-6-19)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read ArticlePegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout
Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades.
Read Article


